TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 264798

Group type: EXPERIMENTAL
Intervention: Cranial irradiation combined with a 3-year course of multiple drug systemic chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preventive cranial irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low dose palliative irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple agent chemotherapy and preventive meningeal irradiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide therapy
Number of subjects: 0
Study: 30580905

Group type: EXPERIMENTAL
Intervention: Psychosexual rehabilitation booklet
Number of subjects: 82

Group type: COMPARATOR
Intervention: Standard information materials (Control)
Number of subjects: 82
Study: 27298379

Group type: EXPERIMENTAL
Intervention: Carvedilol (12±1.67 mg/day)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 140
Study: 25953480

Group type: EXPERIMENTAL
Intervention: Polyacrylamide hydrogel filler
Number of subjects: 31
Study: 24192420

Group type: EXPERIMENTAL
Intervention: Passive-controlling 3D webpages (P3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active-controlling 3D webpages (A3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional 2D webpages (2D)
Number of subjects: 0
Study: 22094037

Group type: EXPERIMENTAL
Intervention: Ephedrine (4 g/L)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ephedrine plus Phenylephrine (ephedrine 2 g/L + phenylephrine 25 mg/L)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Phenylephrine (50 mg/L)
Number of subjects: 90
Study: 19131811

Group type: EXPERIMENTAL
Intervention: Patient model (group II)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mechanical model (group III)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Neither model (group I)
Number of subjects: 70
Study: 21606948

Group type: EXPERIMENTAL
Intervention: Varenicline (standard FDA-approved regimen)
Number of subjects: 397
Study: 16191054

Group type: EXPERIMENTAL
Intervention: Noninvasive continuous monitoring method (NICOMM) using laser-Doppler flowmeter (LDF) at 780 nm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous hematocrit monitor (Crit-Line monitor, CLM)
Number of subjects: 0
Study: 12779280

Group type: EXPERIMENTAL
Intervention: Lidocaine cream (6%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tetracaine cream (4%)
Number of subjects: 0
Study: 10684018

Group type: EXPERIMENTAL
Intervention: 0.82 g.kg‐1.d‐1 fat emulsion (42% of total calorie)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 1.72 g.kg‐1.d‐1 fat emulsion (52% of total calorie)
Number of subjects: 20
Study: 7936382

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Ipriflavone
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Transdermal estrogens
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Fluorine-calcium
Number of subjects: 442

Group type: COMPARATOR
Intervention: Non-treated patients
Number of subjects: 442
Study: 2672426

Group type: EXPERIMENTAL
Intervention: Fludrocortisone acetate
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 91
Study: 322634

Group type: EXPERIMENTAL
Intervention: Affect-arousing, gestalt therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Meditation-Tai Chi (Control)
Number of subjects: 33
Study: 29775202

Group type: EXPERIMENTAL
Intervention: Aspirin 100 μM with 0.05% DMSO
Number of subjects: 13

Group type: COMPARATOR
Intervention: 0.05% DMSO without aspirin
Number of subjects: 13
Study: 26024743

Group type: EXPERIMENTAL
Intervention: Lipegfilgrastim 6 mg once per cycle
Number of subjects: 306

Group type: COMPARATOR
Intervention: Pegfilgrastim 6 mg once per cycle
Number of subjects: 306
Study: 25675651

Group type: EXPERIMENTAL
Intervention: PB U-MDT
Number of subjects: 342

Group type: COMPARATOR
Intervention: PB R-MDT
Number of subjects: 342
Study: 22638902

Group type: EXPERIMENTAL
Intervention: Healthy MOMs Healthy Lifestyle Intervention (MOMs)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Healthy Pregnancy Education (control)
Number of subjects: 275
Study: 20105189

Group type: EXPERIMENTAL
Intervention: rs4410646 genotype (CC)
Number of subjects: 981

Group type: COMPARATOR
Intervention: rs4410646 genotype (AC and AA)
Number of subjects: 981

Group type: EXPERIMENTAL
Intervention: rs7703713 genotype (GA and AA)
Number of subjects: 981

Group type: COMPARATOR
Intervention: rs7703713 genotype (not specified)
Number of subjects: 981
Study: 19038898

Group type: EXPERIMENTAL
Intervention: Type 2 diabetes
Number of subjects: 478

Group type: COMPARATOR
Intervention: Nondiabetic comparison subjects
Number of subjects: 478
Study: 15972580

Group type: EXPERIMENTAL
Intervention: 0.5 microg/d ED-71
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 0.75 microg/d ED-71
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: 1.0 microg/d ED-71
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 219
Study: 12814996

Group type: EXPERIMENTAL
Intervention: Cigarette smoking (>/=25 cigarettes/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Alcohol drinking (>/=5 drinks/day)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Vegetable consumption (highest level)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fruit consumption (highest level)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Olive oil consumption (highest level)
Number of subjects: 68
Study: 10570387

Group type: EXPERIMENTAL
Intervention: 1.8% tetracaine cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 8556225

Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily for 12 weeks
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1816827

Group type: EXPERIMENTAL
Intervention: Collective measures of oral hygiene (monthly, quarterly, half-yearly intervals)
Number of subjects: 442

Group type: EXPERIMENTAL
Intervention: Twice instructed measures of oral hygiene
Number of subjects: 442
Study: 7280450

Group type: EXPERIMENTAL
Intervention: Octavalent vaccine (Eli Lilly Laboratories) given at six months and/or 12 months of age
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 14-valent vaccine (Merck Sharp & Dohme) given at 12 months of age
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unvaccinated controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All groups (including controls) by age 24 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical reactions post-vaccination
Number of subjects: 0
Study: 30712247

Group type: EXPERIMENTAL
Intervention: VKORC1 genetic evaluation
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Warfarin dosing based on genetic testing
Number of subjects: 127
Study: 28844878

Group type: EXPERIMENTAL
Intervention: LNG-IUS 8 using the modified EvoInserter®
Number of subjects: 965
Study: 27363396

Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to (n=16)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Eperisone hydrochloride (n=14)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to (2.5 g as needed)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to (7.5 g/day)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Shakuyaku‐kanzo‐to
Number of subjects: 58
Study: 24118416

Group type: EXPERIMENTAL
Intervention: Psychosocial intervention trial to improve symptoms and quality of life
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Actigraphy (n = 73)
Number of subjects: 143
Study: 21251805

Group type: COMPARATOR
Intervention: Nasal LTB4
Number of subjects: 61
Study: 19878793

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) using RX Acculink stent and RX Accunet embolic protection system
Number of subjects: 2522

Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 2522

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS) and Carotid endarterectomy (CEA)
Number of subjects: 2522
Study: 17761981

Group type: EXPERIMENTAL
Intervention: Docetaxel (two schedules)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Mitoxantrone with prednisone
Number of subjects: 1006
Study: 15227690

Group type: EXPERIMENTAL
Intervention: Carbon dioxide pneumoperitoneum (CLC)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gasless laparoscopic cholecystectomy (GLC)
Number of subjects: 50
Study: 10834424

Group type: EXPERIMENTAL
Intervention: HOE901 (0.4 U/kg body wt)
Number of subjects: 15

Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9138853

Group type: EXPERIMENTAL
Intervention: Nadolol (hydrophilic beta-blocker)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol (lipophilic beta-blocker)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 20
Study: 7681516

Group type: COMPARATOR
Intervention: Oral dofetilide (5 micrograms/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral dofetilide (7.5 micrograms/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral dofetilide (10 micrograms/kg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous dofetilide (0.5 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Oral dofetilide (0.5 mg)
Number of subjects: 18
Study: 2877594

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.08 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Succinylcholine (1.5 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NaCl 0.9% and 0.1 mg fentanyl (control group C)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 0
Study: 29660297

Group type: EXPERIMENTAL
Intervention: Integrated family planning curriculum (intervention school)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Conventional medical curriculum (control schools)
Number of subjects: 217
Study: 27686403

Group type: EXPERIMENTAL
Intervention: 2% CAF solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control condition (no prior glycogen depletion)
Number of subjects: 8
Study: 23937927

Group type: EXPERIMENTAL
Intervention: Intact anterior supraspinatus tendon (Group 1)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Disrupted anterior supraspinatus tendon (Group 2)
Number of subjects: 112
Study: 22969732

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg plus d-amphetamine 30 mg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: d-amphetamine 60 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Modafinil 400 mg
Number of subjects: 73
Study: 20636552

Group type: EXPERIMENTAL
Intervention: Insufflation with dry, room temperature carbon dioxide for 2 minutes
Number of subjects: 10
Study: 19112722

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid 500 mg per day
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg per day
Number of subjects: 18

Group type: COMPARATOR
Intervention: Both groups (Acetylsalicylic acid and Ibuprofen)
Number of subjects: 18
Study: 15996057

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly
Number of subjects: 201
Study: 12427322

Group type: EXPERIMENTAL
Intervention: Waiver of consent used in 62% of patients enrolled during the trial period.
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Time from injury to randomization in the first 9 months was 4.5 ± 1.2 h; time to target temperature was 11.7 ± 2.6 h.
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Waiver of consent usage among different demographics: 53% of minorities, 47% of unskilled workers, 33% of nonminorities, and 29% of skilled or professional workers.
Number of subjects: 392
Study: 10209373

Group type: EXPERIMENTAL
Intervention: Lignocaine 2% with adrenaline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Prilocaine 3% with felypressin 0.03 IU.ml‐1
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% lignocaine and 0.5% bupivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 2% lignocaine
Number of subjects: 60
Study: 7562650

Group type: EXPERIMENTAL
Intervention: Dynamic elastic response feet (DER)
Number of subjects: 17

Group type: COMPARATOR
Intervention: SACH foot
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Traumatic amputees
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Dysvascular amputees
Number of subjects: 17
Study: 2204995

Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 24
Study: 385822

Group type: EXPERIMENTAL
Intervention: Freeze-dried cortical powdered allografts of bone
Number of subjects: 9

Group type: COMPARATOR
Intervention: Flap and curettage control
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Nongrafting procedures
Number of subjects: 9
Study: 30565096

Group type: COMPARATOR
Intervention: Oral semaglutide (2-20 mg semaglutide co-formulated with 150-600 mg SNAC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Oral semaglutide (20 or 40 mg with 300 mg SNAC)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Oral semaglutide (40 mg with 300 mg SNAC)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 158
Study: 29494545

Group type: EXPERIMENTAL
Intervention: Temperature-Cycled Operation (TCO) using a single commercial MOS gas sensor
Number of subjects: 0
Study: 27509601

Group type: EXPERIMENTAL
Intervention: Warming-needle moxibustion
Number of subjects: 61

Group type: COMPARATOR
Intervention: Acupuncture
Number of subjects: 61
Study: 25311998

Group type: EXPERIMENTAL
Intervention: Combination Intervention Strategy (CIS) including point-of-care CD4 count testing, accelerated antiretroviral therapy initiation, SMS reminders for linkage and retention in care
Number of subjects: 2250

Group type: EXPERIMENTAL
Intervention: Combination Intervention Strategy plus Financial Incentives (CIS + FI)
Number of subjects: 2250

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 2250
Study: 22791228

Group type: EXPERIMENTAL
Intervention: Anodal tDCS (10 min, 1 mA)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 6
Study: 20837352

Group type: EXPERIMENTAL
Intervention: 10 g of test oil containing 27.3% DAG
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 10 g of test oil containing 54.6% DAG
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: DAG oil
Number of subjects: 22
Study: 16358297

Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiotherapy
Number of subjects: 0
Study: 16325031

Group type: EXPERIMENTAL
Intervention: Imatinib (600 mg/day for 10 days starting 2 days before repeat intervention)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180

Group type: COMPARATOR
Intervention: Imatinib and Placebo
Number of subjects: 180
Study: 11849868

Group type: EXPERIMENTAL
Intervention: Low-intensity bicycle exercise (45 minutes at 50% maximal oxygen uptake)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Rest (45 minutes)
Number of subjects: 24
Study: 9667294

Group type: EXPERIMENTAL
Intervention: Local ketamine infiltration
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: Systemic ketamine
Number of subjects: 15
Study: 7906539

Group type: EXPERIMENTAL
Intervention: Apraclonidine 1%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pilocarpine 4%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Combined treatment (Apraclonidine 1% and Pilocarpine 4%)
Number of subjects: 75
Study: 2780105

Group type: EXPERIMENTAL
Intervention: Minocycline 200 mg/24 h for 7 days plus saline irrigation of the operative site.
Number of subjects: 171

Group type: COMPARATOR
Intervention: Cefotiam (2 g intraoperatively, 2 g at 12 hours and 24 hours post-surgery) plus Povidone iodine (5% dilution) irrigation of the operative site.
Number of subjects: 171
Study: 1219635

Group type: EXPERIMENTAL
Intervention: Acebutolol (600 to 800 mg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Acebutolol
Number of subjects: 33
Study: 6985706

Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (200 mg four times a day)
Number of subjects: 1558

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1558
Study: 31194885

Group type: EXPERIMENTAL
Intervention: Upadacitinib (15 mg and 30 mg extended-release once daily)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Upadacitinib (twice-daily dosing of immediate-release formulation)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Upadacitinib (extended-release)
Number of subjects: 574
Study: 29493811

Group type: EXPERIMENTAL
Intervention: Housing rent subsidy plus intensive case management (ICM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intensive case management (ICM) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Housing rent subsidy
Number of subjects: 0
Study: 29871185

Group type: EXPERIMENTAL
Intervention: Intratympanic injection with mouse nerve growth factor and methylprednisolone
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conventional medication and methylprednisolone (0.5 ml) + 0.9% NaCl (0.5 ml)
Number of subjects: 149
Study: 24589090

Group type: EXPERIMENTAL
Intervention: Immunonutrition (oral supplementation containing arginine, ω‐3 fatty acids, and RNA for 5 days before surgery)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Immunonutrition
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no artificial nutrition, regular food allowed before surgery)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 22302817

Group type: EXPERIMENTAL
Intervention: Funny stimuli
Number of subjects: 15

Group type: COMPARATOR
Intervention: Positive stimuli
Number of subjects: 15

Group type: COMPARATOR
Intervention: Neutral stimuli
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Younger participants
Number of subjects: 15
Study: 20817383

Group type: EXPERIMENTAL
Intervention: Combined intervention (parent-delivered intervention + BASICS)
Number of subjects: 1275

Group type: EXPERIMENTAL
Intervention: BASICS (Brief Alcohol Screening and Intervention for College Students)
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Assessment-only control
Number of subjects: 1275
Study: 17991638

Group type: COMPARATOR
Intervention: Diet intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Exercise intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Combined diet and exercise intervention
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 188
Study: 15655825

Group type: EXPERIMENTAL
Intervention: HCC vaccine group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 11910388

Group type: EXPERIMENTAL
Intervention: Phase I cardiac rehabilitation intervention (experimental group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonintervention (comparison group)
Number of subjects: 60
Study: 9791816

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK) using an erodible disc and axicon lens
Number of subjects: 21
Study: 7535669

Group type: EXPERIMENTAL
Intervention: Pirenzepine (200 mg orally)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (120 mg orally)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: GH releasing hormone (GHRH) 1‐44 (80 micrograms i.v.)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Diabetic subjects
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Fasting plasma glucose
Number of subjects: 18
Study: 2540285

Group type: EXPERIMENTAL
Intervention: n-3 polyunsaturated fatty acids
Number of subjects: 312

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 312
Study: 15894

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of 50 mg progesterone and 3 mg oestradiol benzoate in oil
Number of subjects: 300

Group type: COMPARATOR
Intervention: No hormonal injection (Control)
Number of subjects: 300
Study: 29428088

Group type: EXPERIMENTAL
Intervention: Parenteral cobalamin (0.4–1.2 mg hydroxycobalamin according to body weight)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Oral cobalamin tablets (0.25–1.0 mg cyanocobalamin daily according to body weight)
Number of subjects: 53
Study: 27616175

Group type: EXPERIMENTAL
Intervention: Frequent group (6 times/week or more)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intermittent group (2 times/week)
Number of subjects: 32
Study: 24980426

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg before surgery followed by 200 mg TID for 4 days
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study: 21920646

Group type: EXPERIMENTAL
Intervention: Group health education programme
Number of subjects: 100
Study: 20397455

Group type: EXPERIMENTAL
Intervention: Acupuncture and herbal medicine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin C and Vitamin E (Control)
Number of subjects: 60
Study: 18473407

Group type: EXPERIMENTAL
Intervention: 7-day therapy (omeprazole 20 mg bid, clarithromycin 500 mg bid, amoxicillin 1 g bid)
Number of subjects: 136

Group type: COMPARATOR
Intervention: 10-day therapy (same medication as group 1)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: 7-day therapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: 10-day therapy
Number of subjects: 136
Study: 16169320

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 12809972

Group type: EXPERIMENTAL
Intervention: Increased copayments in 1995 and 1997 for antidepressants, anxiolytics, and sedatives
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased copayments in 1997 for antidepressants
Number of subjects: 0
Study: 11219596

Group type: EXPERIMENTAL
Intervention: Anatomical M-mode echocardiography
Number of subjects: 124
Study: 9208628

Group type: EXPERIMENTAL
Intervention: Interfon-Alpha (1 million units per day for 5-7 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 31